Covid-19: Should We Infect People With It?
BBC Focus - Science & Technology|September 2020
We're offering this story for free to read so that you can stay updated on the COVID-19 outbreak
Covid-19: Should We Infect People With It?
A vaccine may be available sooner if volunteers are deliberately infected. But is it ethical?
James Lloyd

The race for a COVID-19 vaccine is hotting up. There are currently over 150 candidate vaccines in development around the world, with around 30 being tested on humans.

But for some scientists, the progress isn’t fast enough. There are growing calls for so-called ‘human challenge studies’, which would deliberately infect volunteers with the coronavirus SARS-CoV-2, with the aim of speeding up vaccine development by, according to one paper, as much as several months, potentially saving thousands of lives.

This would be a big ethical leap from current vaccine trials. Currently, a candidate COVID-19 vaccine goes through three phased trials. In the final trial (phase III), up to 10,000 volunteers are given either the candidate vaccine or a placebo. The volunteers then go about their daily lives, and the scientists wait to see who gets infected, and who doesn’t. If the vaccine works, the scientists should see significantly fewer COVID-19 cases in the vaccine group than in the placebo group.

The downside of this approach is that it takes time for volunteers to become infected, especially in countries with falling case numbers. Human challenge studies could potentially speed up the process by giving the candidate vaccine to a much smaller group of volunteers, and then, once the vaccine has triggered an immune response, directly infecting them with the virus. The scientists would monitor how the volunteers respond to the virus, gathering real-time data on the vaccine’s effectiveness.

articleRead

You can read up to 3 premium stories before you subscribe to Magzter GOLD

Log in, if you are already a subscriber

GoldLogo

Get unlimited access to thousands of curated premium stories, newspapers and 5,000+ magazines

READ THE ENTIRE ISSUE

September 2020